Company Overview

Ash Biotech is a start-up biotechnology company, located in Cambridge UK, working in the new area of phenotype-based drug discovery and development. It is is focused on enabling enhanced understanding, at the earliest possible stage, of both the efficacy and safety of potential new drugs; and on the discovery of new uses for "old" drugs. The company is developing and commercially exploiting its proprietary, cutting-edge biology-related technologies for medium- and high-throughput, high-content-based screening of small molecule drugs.

The company operates a lean business model that allows for extensive gearing of its resources through collaborations with scientists working at larger biotechnology and pharmaceutical companies. Ash Biotech's world-class board and management have several decades of combined drug development and technology development experience, and have been responsible for bringing multiple drugs from discovery to clinical development, including the blockbuster antibody drug, Humira. They have also achieved several "world firsts" in pioneering the development the company's new technologies for phenotype-based drug discovery and development.

Investors

The company was initially financed by the founders, and has been profitable since that date through research collaborations with biotechnology and pharmaceutical companies. These revenue streams, along with the deal structures the company has negotiated, have enabled Ash Biotech to: build up world-class IP and know-how in key emerging aspects of drug discovery and development; and fund the development of an innovative new technology platform, and products that derive from that platform, that enable the commercial exploitation of the company's unique IP and know-how.

About The Founders

The Ash Biotech team has decades of experience in small biotech, big biotech and big pharma; from the lab bench to the board room. Our management team, previously the management team for Technology Division of Cambridge Antibody Technology, is one of the most successful in European biotechnology. The team has played key roles in growing biotech/pharma companies in Europe and the US to a combined value of over two and a half billion dollars.